Allarity Therapeutics Files 8-K Report
Ticker: ALLR · Form: 8-K · Filed: Jul 23, 2024 · CIK: 1860657
Sentiment: neutral
Topics: sec-filing, 8-k, regulation-fd
TL;DR
Allarity Therapeutics filed a routine 8-K, no major news.
AI Summary
On July 22, 2024, Allarity Therapeutics, Inc. filed an 8-K report to disclose information regarding a Regulation FD disclosure and financial statements. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates that Allarity Therapeutics is adhering to its reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not disclose any new material events, financial results, or significant changes.
Key Players & Entities
- Allarity Therapeutics, Inc. (company) — Registrant
- July 22, 2024 (date) — Date of earliest event reported
- 24 School Street, 2nd Floor, Boston, MA 02108 (location) — Principal executive offices address
FAQ
What is the primary purpose of this 8-K filing by Allarity Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report under Regulation FD and to provide financial statements and exhibits, as indicated by the filing's item information.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is July 22, 2024.
What is the principal executive office address for Allarity Therapeutics, Inc.?
The principal executive office address for Allarity Therapeutics, Inc. is 24 School Street, 2nd Floor, Boston, MA 02108.
Under which section of the Securities Exchange Act of 1934 is this Current Report filed?
This Current Report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Does this 8-K filing disclose any specific new material events or financial results?
Based on the provided text, this 8-K filing is a standard report and does not explicitly disclose any specific new material events or detailed financial results beyond the reporting categories.
Filing Stats: 430 words · 2 min read · ~1 pages · Grade level 10.5 · Accepted 2024-07-23 16:05:17
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ALLR The Nasdaq Stock Mar
Filing Documents
- ea0209822-8k_allarity.htm (8-K) — 27KB
- ea020982201ex99-1_allarity.htm (EX-99.1) — 23KB
- ex99-1_001.jpg (GRAPHIC) — 18KB
- 0001213900-24-063581.txt ( ) — 252KB
- allr-20240722.xsd (EX-101.SCH) — 3KB
- allr-20240722_lab.xml (EX-101.LAB) — 33KB
- allr-20240722_pre.xml (EX-101.PRE) — 22KB
- ea0209822-8k_allarity_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On July 22, 2024, Allarity Therapeutics, Inc. (the "Company"), issued a press release outlining the Company's progress in 2024 and future objectives. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated July 22, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Allarity Therapeutics, Inc. By: /s/ Thomas H. Jensen Thomas H. Jensen Chief Executive Officer Dated: July 23, 2024 2